Group 1 - The company announced adjustments to the proposed investment amount and internal investment structure of the raised funds to ensure the smooth implementation of fundraising projects and improve the efficiency of fund usage [1][2][5] - The total amount raised from the initial public offering was RMB 1,090.1943 million, with a net amount of RMB 977.8911 million after deducting various issuance costs [1][2][25] - The company established a special account for the management and use of raised funds, which have been fully deposited in the account approved by the board of directors [1][25] Group 2 - The company adjusted the internal investment structure of the "Dialyzer (Ganzhou) Production Project" to prioritize construction costs over equipment purchases, ensuring efficient use of funds [3][5] - The adjustments will not change the total investment amount for the project, and the company plans to use self-raised funds for future equipment purchases as needed [3][5] Group 3 - The adjustments made by the company are based on actual fundraising conditions and business strategy, ensuring compliance with regulations and protecting shareholder interests [5][7][9] - The board of directors and the supervisory board approved the adjustments during meetings held on May 27, 2025, without the need for shareholder approval [6][17][41] Group 4 - The company plans to use up to RMB 170 million of the raised funds to increase capital in its wholly-owned subsidiary, Ganzhou Blood Purification Products Co., Ltd., to support the implementation of the fundraising project [12][13][14] - The increase in capital will be based on the funding needs of the subsidiary and will be executed within the approved limit [13][14] Group 5 - The company intends to use temporarily idle raised funds for cash management, with a maximum amount of RMB 740 million, to enhance fund efficiency and increase returns for shareholders [22][23][24] - The cash management will involve purchasing low-risk, liquid principal-protected products, ensuring that it does not affect the construction of fundraising projects [23][27][34] Group 6 - The company will replace self-raised funds previously invested in fundraising projects and paid issuance costs with raised funds, totaling RMB 27.67426 million [62][64][67] - This replacement will not affect the normal implementation of fundraising projects and complies with relevant regulations [67][69]

Core Viewpoint - The company intends to extend the repayment of idle raised funds and continue using them for temporary working capital, ensuring that this does not affect the normal progress of fundraising investment projects [4][8]. Fundraising Basic Situation - The company issued 57,459,099 shares at a total fundraising amount of 158,069.98 million RMB, which has been verified by an accounting firm [2][3]. - The funds are stored in a special account and are subject to a tripartite supervision agreement with the sponsor and the bank [2]. Fundraising Investment Projects and Usage - The total investment for the projects is 323,154.01 million RMB, with 156,987.12 million RMB planned to be funded by the raised funds [2]. - As of May 22, 2025, 75,590.62 million RMB of the raised funds have been used, leaving 81,396.5 million RMB available [2]. Previous Use of Idle Funds - The company previously approved the temporary use of up to 70,000 million RMB of idle funds for working capital, with a usage period not exceeding 12 months [4]. Current Proposal for Idle Funds - The company proposes to extend the repayment of up to 70,000 million RMB of idle funds for temporary working capital, with a usage period not exceeding 12 months [5][6]. - This decision is based on the need to stabilize cash flow and improve the efficiency of fund usage, potentially saving about 21 million RMB in financial costs [5]. Review Procedures and Opinions - The board of directors and the supervisory board have approved the proposal, confirming that it does not change the purpose of the raised funds and will not adversely affect the investment projects [6][8]. - Independent directors agree that the proposal meets legal requirements and benefits the company and shareholders [6][8]. Sponsor's Verification Opinion - The sponsor has verified that the proposal complies with relevant regulations and does not change the purpose of the raised funds, ensuring the normal progress of investment projects [7][8].

Core Viewpoint - The company has decided to postpone the repayment of idle raised funds and continue using them to temporarily supplement working capital, which is deemed a reasonable financial arrangement based on the progress of investment projects [1][2]. Group 1 - The sixth supervisory board meeting of the company was held on May 27, 2025, with all three supervisors present [1]. - The supervisory board concluded that the decision to extend the repayment of idle funds is beneficial for reducing financial expenses and improving the efficiency of fund utilization [1]. - The supervisory board confirmed that this decision does not alter the intended use of the raised funds or harm shareholder interests [1]. Group 2 - The resolution to extend the repayment of idle funds was passed unanimously with three votes in favor and no votes against or abstentions [2].

南京公用发展股份有限公司 （尚需经公司股东大会审议通过） 二○二五年五月 南京公用发展股份有限公司 第一章 总则 第一条 为规范公司募集资金的管理和使用，最大限度地保障投资者的利益， 依据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股 票上市规则》《首次公开发行股票注册管理办法》《上市公司证券发行注册管理 办法》《上市公司信息披露管理办法》等法律、法规及《公司章程》的有关规定， 结合公司的实际情况，制定本制度。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。募集资金不得用于持有财务性投 资，不得直接或者间接投资于以买卖有价证券为主要业务的公司。 第四条 公司应当建立并完善募集资金存放、管理、使用、改变用途、监督 和责任追究的内部控制制度，明确募集资金使用的分级审批权限、决策程序、风 险控制措施及信息披露要求，规范使用募集资金。 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防范投资风 险，提高募集资金使用效益。 第五条 公司的控股股东、实际控制人 ...

Group 1 - The company held the 19th meeting of the 11th Board of Directors on May 27, 2025, with all 5 directors present, achieving a 100% attendance rate [1] - The meeting discussed and approved adjustments to the company's organizational structure to enhance management efficiency and governance [1] - The company plans to open two special accounts for raised funds in its subsidiary, Guoguang Acoustics (Vietnam) Co., Ltd., and authorized management to sign supplementary agreements for fund supervision [2]

Fundraising Overview - The company raised a total of RMB 1,112,999,994.00 through a non-public offering of 82,444,444 shares at a price of RMB 13.50 per share, with a net amount of RMB 1,089,457,834.00 after deducting issuance costs [1][2] - The funds were deposited in a special account at China Construction Bank, with a tripartite supervision agreement signed with Huatai United Securities [2] Fund Usage and Account Closure - The special account for fundraising has been fully utilized, with a remaining balance of RMB 2,589.4 transferred to the company's own funds, leading to the account's closure [3] - The company has completed the account cancellation procedures, terminating the tripartite supervision agreement with the bank and the securities firm [3] Guarantee Situation - The company signed a loan agreement with Zhongyuan Bank for RMB 37.4 million, with its wholly-owned subsidiary providing a joint liability guarantee [8] - The total guarantee amount provided by the company and its subsidiaries exceeds 100% of the latest audited net assets, with specific figures indicating a total guarantee balance of RMB 108,963.38 million, which is 170.98% of the latest audited net assets [8][13] Company Information - The company, Linzhou Heavy Machinery Group Co., Ltd., was established on May 8, 2002, with a registered capital of RMB 816,370,000 [9] - The company operates in the manufacturing and sales of coal mining machinery, explosion-proof electrical appliances, and other related services [9]

根据中国证券监督管理委员会《关于同意浙江华海药业股份有限公司向特定对象发行股票注册的批复》 （证监许可〔2024〕480号），浙江华海药业股份有限公司（以下简称"公司"）向特定对象发行人民币 普通股（A股）数量为41,152,263股，发行价格为14.58元/股，募集资金总额为599,999,994.54元，扣除发 行费用17,680,629.03元（不含增值税）后，募集资金净额为582,319,365.51元。上述募集资金已于2025年 3月14日全部到位。天健会计师事务所（特殊普通合伙）对上述募集资金到位情况进行了审验，并出具 了《验资报告》（天健验〔2025〕48号）。 二、募集资金三方监管协议的签订情况 为提高募集资金的使用效率，减少财务费用，降低公司运营成本，维护投资者的利益，在确保募集资金 项目建设的资金需求以及募集资金使用计划正常进行的前提下，公司计划使用部分闲置募集资金暂时补 充流动资金（仅限于与公司主营业务相关的生产经营使用），总额不超过人民币1.81亿元，使用期限不 超过12个月，自公司第八届董事会第三次会议审议通过之日（2025年4月28日）起计算。公司将严格按 照中国证监会、上海证券交 ...

Group 1 - The company Zhejiang Taihong Wanli Technology Co., Ltd. has successfully completed its initial public offering (IPO) of 85.10 million shares at a price of 8.60 RMB per share, raising a total of 731.86 million RMB, with a net amount of 628.78 million RMB after deducting issuance costs [2][3] - The company has established a special account for the raised funds and signed a four-party supervision agreement involving the company, its wholly-owned subsidiary Hebei Xintaihong Auto Parts Co., Ltd., the bank, and the sponsor [3][4] - The board of directors has approved the use of up to 175 million RMB of the raised funds to provide loans to its subsidiary for the expansion project of the "Hebei Wangdu Auto Stamping and Welding Sub-assembly Expansion Project" [3][4] Group 2 - The special account for the raised funds has been opened at Shanghai Pudong Development Bank, with the account number provided, and as of May 26, 2025, the account balance is 0 RMB [4][5] - The agreement stipulates that the funds in the special account can only be used for the designated project and cannot be used for other purposes [4][5] - The sponsor is responsible for supervising the use of the raised funds and must conduct regular checks and provide reports on the account status [5][6]

Core Viewpoint - Sangfor Health plans to temporarily use surplus funds from several projects to supplement working capital and adjust the investment amounts for certain fundraising projects [1][12]. Fundraising Basic Situation - The company was approved to publicly issue 61,621,142 shares at a price of RMB 28.18 per share, raising a total of approximately RMB 1.736 billion, with a net amount of about RMB 1.634 billion after deducting fees [2][3]. Adjustments to Fundraising Projects - The company intends to reduce the investment amount for the "Innovative Antibody Drug Industrialization and Digital Factory Construction Project" from RMB 400 million to RMB 320 million, a reduction of RMB 80 million [1][6]. - The investment for the "Self-immune and Ophthalmic Disease Antibody Drug New Drug R&D Project" will be increased from RMB 610 million to RMB 690 million [1][6]. Surplus Fund Usage Plan - As of April 30, 2025, surplus funds from completed projects will be used to temporarily supplement working capital, amounting to RMB 66.6282 million [4][10]. - The surplus funds will be transferred to the "Supplementary Working Capital Project" account, with a usage period not exceeding 12 months from the date of shareholder meeting approval [4][10]. Reasons for Adjustments - The adjustments are made to enhance the efficiency of fund usage and align with the company's strategic focus on self-immune diseases and inflammation, which have significant unmet clinical needs [6][10]. - The company has shifted focus from certain oncology projects to prioritize self-immune disease projects, reflecting changes in market conditions [4][10]. Board and Supervisory Committee Approval - The board of directors and the supervisory committee have both approved the proposal to use surplus funds for working capital and adjust project investments, emphasizing that these actions will not harm the interests of shareholders [11][12].

国金证券股份有限公司（以下简称"保荐机构"）为立达信物联科技股份有 限公司（以下简称"立达信"或"公司"）首次公开发行股票并上市的保荐机构， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》《上市公司监管指引第2号——上市公司募 集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海证券交 易所上市公司自律监管指引第1号——规范运作》等有关规定，对立达信将部分 募投项目节余募集资金用于其他募投项目及部分募投项目延期的事项进行了核 查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额及到位时间 经中国证券监督管理委员会《关于核准立达信物联科技股份有限公司首次公 开发行股票的批复》 （证监许可〔2021〕2186 号）核准，公司向社会公开发行人 民币普通股（A 股）5,000 万股，每股面值为人民币 1.00 元，发行价格为人民币 万元（不含增值税）后，实际募集资金净额为人民币 77,135.33 万元。 国金证券股份有限公司关于立达信物联科技股份有限公司 将部分募投项目节余募集资金用于其他募投项目及部分募投项 目延期的核查意见 前述 ...